Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.42 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.37 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245092 | 0.89 | BTK (0.43) | BTKNUDT14NUDT5EGFRADK | |
| SCHEMBL16245325 | 0.84 | BTK (0.42) | BTKNUDT14NUDT5EGFRJAK3 | |
| SCHEMBL16245115 | 0.82 | JAK3 (0.48) | JAK3 | |
| SCHEMBL15032829 | 0.82 | METTL3 (0.34) | BTKEGFRADKKCNH2IGF1R | |
| SCHEMBL16245368 | 0.82 | BTK (0.40) | BTKNUDT14NUDT5EGFRADK | |
| SCHEMBL16245276 | 0.81 | BTK (0.39) | BTKNUDT14NUDT5EGFRADK | |
| SCHEMBL16245061 | 0.81 | JAK3 (0.39) | BTKNUDT14NUDT5EGFRJAK3 | |
| SCHEMBL16245006 | 0.81 | BTK (0.39) | BTKNUDT14NUDT5EGFRJAK3 | |
| SCHEMBL16245217 | 0.81 | BTK (0.41) | BTKNUDT14NUDT5EGFRADK | |
| SCHEMBL16245238 | 0.80 | BTK (0.40) | BTKNUDT14NUDT5EGFRADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788000-B1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-8993756-B2 | Pyrrolopyrimidines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349998-A1 | PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS | JAK3, JAK1, JAK2 | BTK 219/4885NUDT14 1448/4885NUDT5 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.